分子核医学在甲状腺癌影像诊断与靶向治疗中的应用进展

doi:10.7538/tws.2013.26.02.0115

摘要/Abstract

摘要：

甲状腺癌是内分泌系统常见的肿瘤之一,不同病理类型的甲状腺癌的生物学行为及预后迥异。近年来，分子核医学已在甲状腺癌的诊断、治疗方面取得了重要的研究进展。结合新的显像剂及SPECT/CT、PET/CT等显像设备的应用，分子核医学可实现在细胞和分子水平上定性和定量显示甲状腺癌特定分子的表达及其水平的变化，并可实现靶向治疗。本文综述了国内外有关分子核医学在甲状腺癌影像诊断及靶向治疗中的应用进展。

关键词: 甲状腺癌, 分子核医学, 靶向治疗

Abstract:

Thyroid carcinoma is themost common malignancy of endocrine system. Different pathologicalclassifications of thyroid carcinoma differ greatly in biological behavior andprognosis. As a newly-emerging subject, molecular nuclear medicine has maderapid advances in both diagnosis and treatment of thyroid carcinoma. With theapplication of new imaging agents and devices such as SPECT/CT and PET/CT,molecular nuclear imaging can demonstrate, both qualitatively andquantitatively, the alterations in specific molecules of thyroid cancer oncellular and molecular level. Meanwhile, it is capable of utilizingradiopharmaceuticals to target specifically to these molecules. Here we presenta review on the latest progresses in this field.

Key words: thyroid cancer, molecular nuclear medicine, targeted treatment

LI Chun-yan;YANG Yu-hui;GAO Zai-rong. 分子核医学在甲状腺癌影像诊断与靶向治疗中的应用进展[J]. 同位素, 2013, 26(2): 115-121.

李春艳;杨宇辉;高再荣. The Application ofMolecular Nuclear Medicine in Imaging Diagnosis and Targeted Treatment ofThyroid Carcinoma[J]. Journal of Isotopes, 2013, 26(2): 115-121.

参考文献

[1]Cooper DS, Doherty GM, Haugen BR, et al. RevisedAmerican Thyroid Association management guidelines for patients with thyroidnodules and differentiated thyroid cancer[J]. Thyroid, 2009, 19(11): 1167-1214.

[2]Tharp K, Israel O, Hausmann J, et al. Impact of ¹³¹I-SPECT/CT images obtained with an integrated system in the follow-upof patients with thyroid carcinoma[J]. Eur J Nucl Med Mol Imaging, 2004,31(10): 1435-1442.

[3]Ingui CJ, Shah NP, Oates ME. Endocrine neoplasmscintigraphy: added value of fusing SPECT/CT images compared with traditionalside-by-side analysis[J]. Clin Nucl Med, 2006, 31(11): 665-672.

[4]Chen L, Luo Q, Shen Y, et al. Incremental value of ¹³¹I-SPECT /CT in the management of patients with differentiated thyroid carcinoma[J].J Nucl Med, 2008, 49(12): 1952-1957.

[5]Schmidt D, Szikszai A, Linke R, et al. Impact of ¹³¹I-SPECT/spiral CT on nodal staging of differentiated thyroid carcinoma at thefirst radioablation[J]. J Nucl Med, 2009, 50(1): 18-23.

[6]Kohlfuerst S, Igerc I, Lobnig M, et al.Posttherapeutic (131)I SPECT-CT offers high diagnostic accuracy when thefindings on conventional planar imaging are inconclusive and allows a tailoredpatient treatment regimen[J]. Eur J Nucl Med Mol Imaging, 2009, 36(6): 886-893.

[7]Aide N, Heutte N, Rame JP, et al. Clinicalrelevance of single-photon emission computed tomography/computed tomography ofthe neck and thorax in postablation (131)I scintigraphy for thyroid cancer[J].J Clin Endocrinol Metab, 2009, 94(6): 2 075-2084.

[8]Grewal RK, Tuttle RM, Fox J, et al. The effect ofposttherapy ¹³¹I -SPECT/CT on risk classification and management ofpatients with differentiated thyroid cancer[J]. J Nucl Med, 2010, 51(9): 1361-1367.

[9]Liu FT, Rabinovich GA. Galectins as modulators oftumour progression[J]. Nat Rev Cancer, 2005, 5(1): 29-41.

[10]Bartolazzi A, Bellotti C, Sciacchitano S.Methodology and technical requirements of the galectin-3 test for thepreoperative characterization of thyroid nodules[J]. Appl Immunohistochem MolMorphol, 2012, 20(1): 2-7.

[11]Bartolazzi A, D'Alessandria C, Parisella MG, etal. Thyroid cancer imaging in vivo by targeting the anti-apoptotic moleculegalectin-3[J]. PLoS One, 2008, 3(11): e3768.

[12]Haslinghuis LM, Krenning EP, De Herder WW, et al.Somatostatin receptor scintigraphy in the follow-up of patients withdifferentiated thyroid cancer[J]. J Endocrinol Invest, 2001, 24(6): 415-422.

[13]Giammarile F, Houzard C, Bournaud C, et al.Diagnostic management of suspected metastatic thyroid carcinoma: clinical valueof octreotide scintigraphy in patients with negative high-dose radioiodinescans[J]. Eur J Endocrinol, 2004, 150(3): 277-283.

[14]De Jong M, Valkema R, Jamar F, et al. Somatostatinreceptor-targeted radionuclide therapy of tumors: preclinical and clinicalfindings[J]. Semin Nucl Med, 2002, 32(2): 133-140.

[15]Teunissen JJ, Kwekkeboom DJ, Kooij PP, et al.Peptide receptor radionuclide therapy for non-radioiodine-avid differentiatedthyroid carcinoma[J]. J Nucl Med, 2005, 46 Suppl 1:107S-114S.

[16]Kim HJ, Kim YH, Lee DS, et al. In vivo imaging offunctional targeting of miR-221 in papillary thyroid carcinoma[J]. J Nucl Med,2008, 49(10): 1686-1693.

[17]Joensuu H, Ahonen A. Imaging of metastases ofthyroid carcinoma with fluorine-18 fluorodeoxyglucose[J]. J Nucl Med, 1987,28(5): 910-914.

[18]Bertagna F, Bosio G, Biasiotto G, et al. F-18 FDG-PET/CTevaluation of patients with differentiated thyroid cancer with negative I-131total body scan and high thyroglobulin level[J]. Clin Nucl Med, 2009, 34(11):756-761.

[19]Freudenberg LS, Frilling A, Kuhl H, et al. Dual-modalityFDG-PET/CT in follow-up of patients with recurrent iodine-negativedifferentiated thyroid cancer[J]. Eur Radiol, 2007, 17(12): 3139-3147.

[20]Al-Nahhas A, Khan S, Gogbashian A, et al. Review.¹⁸F-FDGPET in the diagnosis and follow-up of thyroid malignancy[J]. In Vivo, 2008,22(1): 109-114.

[21]Miller ME, Chen Q, Elashoff D, et al. Positronemission tomography and positron emission tomography-CT evaluation forrecurrent papillary thyroid carcinoma: meta-analysis and literature review[J].Head Neck, 2011, 33(4): 562-565.

[22]Dong MJ, Liu ZF, Zhao K, et al. Value of ¹⁸F-FDGPET/PET-CT in differentiated thyroid carcinoma with radioiodine negative whole bodyscan: a meta-analysis[J]. Nucl Med Commun, 2009, 30(8): 639-650.

[23]Razfar A, Branstetter BFt, Christopoulos A, et al.Clinical usefulness of positron emission tomography-computed tomography inrecurrent thyroid carcinoma[J]. Arch Otolaryngol Head Neck Surg, 2010, 136(2):120-125.

[24]Robbins RJ, Wan Q, Grewal RK, et al. Real-timeprognosis for metastatic thyroid carcinoma based on 2-[¹⁸F]fluoro-2-deoxy-D-Glucose-positronemission tomography scanning[J]. J Clin Endocrinol Metab, 2006, 91(2): 498-505.

[25]Yoshio K, Sato S, Okumura Y, et al. The localefficacy of I-131 for F-18 FDG PET positive lesions in patients with recurrentor metastatic thyroid carcinomas[J]. Clin Nucl Med, 2011, 36(2): 113-117.

[26]Lowe VJ, Mullan BP, Hay ID, et al. ¹⁸F-FDGPET of patients with Hurthle cell carcinoma[J]. J Nucl Med, 2003, 44(9): 1402-1406.

[27]Phan HT, Jager PL, Plukker JT, et al. Comparisonof ¹¹C-methionine PET and ¹⁸F-fluorodeoxyglucose PET indifferentiated thyroid cancer[J]. Nucl Med Commun, 2008, 29(8): 711-716.

[28]Arslan N, Ilgan S, Yuksel D, et al. Comparison ofIn-111 octreotide and Tc-99m (V) DMSA scintigraphy in the detection ofmedullary thyroid tumor foci in patients with elevated levels of tumor markersafter surgery[J]. Clin Nucl Med, 2001, 26(8): 683-688.

[29]Nock BA, Maina T, Behe M, et al. CCK-2/gastrinreceptor-targeted tumor imaging with (99m)Tc-labeledminigastrin analogs[J]. J Nucl Med, 2005, 46(10): 1727-1736.

[30]Gao Z, Biersack HJ, Ezziddin S, et al. The role ofcombined imaging in metastatic medullary thyroid carcinoma: ¹¹¹In-DTPA-octreotideand ¹³¹I /123I-MIBG as predictors for radionuclide therapy[J]. JCancer Res Clin Oncol, 2004, 130(11): 649-656.

[31]de Groot JW, Links TP, Jager PL, et al. Impact of ¹⁸F-fluoro-2-deoxy-D-Glucosepositron emission tomography (FDG-PET) in patients with biochemicalevidence of recurrent or residual medullary thyroid cancer[J]. Ann Surg Oncol,2004, 11(8): 786-794.

[32]Ong SC, Schoder H, Patel SG, et al. Diagnosticaccuracy of ¹⁸F-FDG PET in restaging patients with medullary thyroidcarcinoma and elevated calcitonin levels[J]. J Nucl Med, 2007, 48(4): 501-507.

[33]Skoura E, Rondogianni P, Alevizaki M, et al. Roleof [(18)F]FDG-PET/CT in the detection of occult recurrent medullary thyroidcancer[J]. Nucl Med Commun, 2010, 31(6): 567-575.

[34]Bogsrud TV, Karantanis D, Nathan MA, et al. Theprognostic value of 2-deoxy-2-[¹⁸F]fluoro-D-Glucose positronemission tomography in patients with suspected residual or recurrent medullarythyroid carcinoma[J]. Mol Imaging Biol, 2010, 12(5): 547-553.

[35]Oudoux A, Salaun PY, Bournaud C, et al.Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucoseand sensitivity of immunoscintigraphy in patients with medullary thyroidcarcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy[J].J Clin Endocrinol Metab, 2007, 92(12): 4590-4597.

[36]Hoegerle S, Altehoefer C, Ghanem N, et al.¹⁸F-DOPApositron emission tomography for tumour detection in patients with medullarythyroid carcinoma and elevated calcitonin levels[J]. Eur J Nucl Med, 2001,28(1): 64-71.

[37]Cengic N, Baker CH, Schutz M, et al. A noveltherapeutic strategy for medullary thyroid cancer based on radioiodine therapyfollowing tissue-specific sodium iodide symporter gene expression[J]. JClin Endocrinol Metab, 2005, 90(8): 4457-4464.

[38]Bogsrud TV, Karantanis D, Nathan MA, et al. ¹⁸F-FDGPET in the management of patients with anaplastic thyroid carcinoma[J].Thyroid, 2008, 18(7): 713-719.

[39]Poisson T, Deandreis D, Leboulleux S, et al. ¹⁸F-fluorodeoxyglucosepositron emission tomography and computed tomography in anaplastic thyroidcancer[J]. Eur J Nucl Med Mol Imaging, 2010, 37(12): 2277-2285.

[40]Lee YJ, Chung JK, ShinJH, et al. In vitro and in vivo properties of a human anaplastic thyroid carcinomacell line transfected with the sodium iodide symporter gene[J]. Thyroid, 2004,14(11): 889-895.